Oncología Traslacional
ONCTRAS
Klinikum der Universität München
Múnich, AlemaniaPublikationen in Zusammenarbeit mit Forschern von Klinikum der Universität München (9)
2024
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
2022
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
2021
-
Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic
British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96
2020
-
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
International Journal of Cancer, Vol. 146, Núm. 2, pp. 439-448
2019
-
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428
2018
-
Is there a role for HIPEC in ovarian cancer?
Archives of Gynecology and Obstetrics
-
Safety and dose modification for patients receiving niraparib
Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792